التفاصيل البيبلوغرافية
| العنوان: |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies |
| المؤلفون: |
de la Rubia, Javier1, Regadera, Ana I.1, Martın, Guillermo1, Cervera, José1, Sanz, Guillermo F.1, Martınez, Jesús A.1, Jarque, Isidro1, Garcıa, Inmaculada1, Andreu, Rafael1, Moscardó, Federico1, Jiménez, Carmen1, Mollá, Susana1, Benlloch, Luis1, Sanz, Miguel A. msanz@uv.es |
| المصدر: |
Leukemia Research. Aug2002, Vol. 26 Issue 8, p725. 6p. |
| مصطلحات موضوعية: |
*MYELOID leukemia, *FLUDARABINE |
| مستخلص: |
Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity. [Copyright &y& Elsevier] |
| قاعدة البيانات: |
Academic Search Index |
